ライフサイエンスコーパス: off-label use

1 ved crizotinib therapy through an individual off-label use.

2 for Food and Drug Administration-approved or off-label use.

3 , with concomitant increases in dabigatran's off-label use.

4 e and duration of treatment as well as their off-label use.

5 among atypical antipsychotic medications for off-label use.

6 ere weakly associated with the likelihood of off-label use.

7 ontin, Pfizer, Inc., New York, New York) for off-label uses.

8 for Food and Drug Administration-approved or off-label use (0.74% vs 0.67%; p = 0.336; 33 vs 31 event

9 site end point was significantly higher with off-label use (adjusted hazard ratio [HR], 2.08; 95% con

10 s end point was not different at 1 year with off-label use (adjusted HR, 1.10; 95% CI, 0.79-1.54; P =

11 essel revascularization were associated with off-label use (adjusted HR, 1.49; 95% CI, 1.13-1.98; P =

12 reactions do not occur more frequently with off-label use, adverse drug reaction risk increases with

13 On-label use amounted to 70%, and off-label use amounted to 30%.

14 ce of adverse drug reactions associated with off-label use and evaluate off-label use as a risk facto

15 Excluding off-label use and pregnancy, 438 patients (78.6%) did no

16 ard use, relative early safety is lower with off-label use, and the long-term effectiveness is lower

17 s associated with off-label use and evaluate off-label use as a risk factor for the development of ad

18 ibed promotion of the same drug for the same off-label use as was alleged by whistleblowers in the US

19 eterization laboratory-only eptifibatide (an off-label use) as procedural pharmacotherapy for patient

20 %), with hospitals in the highest tertile of off-label use associated with increased 30-day adverse c

21 re safe and efficacious in both on-label and off-label use but highlight differences between RCT and

22 rials in children, which might reduce unsafe off-label use by promoting more quickly proper labeling

23 re not approved for use in the forehead, but off-label use for enhancement in this region is common.

24 EDTA chelation therapy has been in off-label use for the treatment of atherosclerosis.

25 The CMS would pay only for off-label uses for which there is adequate evidence in i

26 seven ADRs lacking PI changes occurred with off-label use, for which PI change is not recommended by

27 Off-label use has been promoted because of the paucity o

28 is common in the ICU; however, the safety of off-label use has not been assessed.

29 ations, their unanticipated side effects and off-label use have contributed significantly to our unde

30 disclosures made in articles related to the off-label use in question, determined the frequency of a

31 Novel "off-label" uses in children for interleukin-1 receptor a

32 The extent of off-label use is a policy concern because the clinical b

33 tor medication in the United States, but its off-label use is associated with risks associated with t

34 Prior research indicates that off-label use is common in the ICU; however, the safety

35 Off-label use is composed of a roughly equal mix of chem

36 position) and articles (type, connection to off-label use, journal impact factor, citation count/yea

37 gle intravitreal injection of bevacizumab in off-label use (n = 33 eyes) or peripheral laser ablation

38 Off-label use occurred in 54.7% of all patients with bar

39 In addition, off-label use of a third anti-VEGF agent, bevacizumab, a

40 MLV-related viruses, including XMRV, and the off-label use of antiretrovirals for the treatment of CF

41 It could be argued that all off-label use of any agent should be deemed illegal.

42 While investigating the off-label use of BDQ as salvage therapy, seven of 13 pat

43 pares annulus measurements from 3D-TEE using off-label use of commercially available software with MD

44 eosinophilic esophagitis (EoE) is limited to off-label use of corticosteroids not optimized for esoph

45 eosinophilic esophagitis (EoE) is limited to off-label use of corticosteroids not optimized for esoph

46 yrin production, we treated the patient with off-label use of deferasirox to maintain iron deficiency

47 Recent reports suggest that off-label use of drug-eluting stents is associated with

48 Compared with on-label use, off-label use of drug-eluting stents is associated with

49 , highlighting the risks associated with the off-label use of drugs in newborn infants before safety

50 because of access to clinical trials and/or off-label use of drugs.

51 rend continued until the mid-1990s, when the off-label use of fenfluramine plus phentermine (fen-phen

52 Studies in the literature suggest that the off-label use of fibrin glue to close limbal conjunctiva

53 ed selective outcome reporting for trials of off-label use of gabapentin.

54 ugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected pe

55 We also discuss off-label use of medications studied for obesity and pro

56 the design of future prospective trials for off-label use of oncology drugs across four areas: trial

57 For now, decisions about off-label use of recombinant factor VIIa remain at the p

58 From 2000 to 2008, off-label use of rFVIIa in hospitals increased more than

59 Off-label use of rFVIIa in the hospital setting far exce

60 rent antiarenaviral therapy is limited to an off-label use of ribavirin that is only partially effect

61 antiarenaviral therapy being limited to the off-label use of ribavirin that is only partially effect

62 rent antiarenaviral therapy is limited to an off-label use of ribavirin that is only partially effect

63 rent antiarenaviral therapy is limited to an off-label use of ribavirin that is only partially effect

64 ile antiarenaviral therapy is limited to the off-label use of ribavirin, which is only partially effe

65 and antiarenaviral therapy is limited to the off-label use of ribavirin, which is only partially effe

66 To evaluate patterns and adverse outcomes of off-label use of TAVR in US clinical practice.

67 Off-label use of TAVR.

68 art failure code was evaluated for potential off-label use of the drug.

69 t therapeutic intervention is limited to the off-label use of the wide-spectrum antiviral ribavirin.

70 Off-label use of transcatheter aortic and pulmonary valv

71 Off-label use of VPA and other HDAC inhibitors for the t

72 Trials were for off-label uses of gabapentin sponsored by Pfizer and Par

73 al companies have paid physicians to promote off-label uses of their products through a number of dif

74 Finally, "off-label" use of intravenous Ig has been evaluated for

75 rent antiarenaviral therapy is limited to an off-labeled use of the nucleoside analog ribavirin, whic

76 cally appropriate cancer therapies including off-label uses recognized by established drug compendia

77 th Food and Drug Administration-approved and off-label use, respectively.

78 N-supported off-label indication, and 10% of off-label use was associated with an FDA-approved cancer

79 Off-label use was defined as use in restenotic lesions,

80 All other use was "off-label." Off-label use was divided by whether it conformed to Nat

81 rventions were excluded, however, risk after off-label use was not significantly increased (P=0.23).

82 physician, and hospital characteristics with off-label use were explored with multivariable hierarchi

83 ependently associated with increased odds of off-label use, whereas diabetes mellitus, increasing age

84 Delays in evaluation may result in off-label use without dosing information as the only acc